Skip to main content
Clinical Trials/EUCTR2005-003021-19-GB
EUCTR2005-003021-19-GB
Active, not recruiting
Not Applicable

The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer - SELENIB

niversity Of Birmingham0 sitesSeptember 18, 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
on-muscle-invasive transitional cell carcinoma of the bladder
Sponsor
niversity Of Birmingham
Status
Active, not recruiting
Last Updated
13 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 18, 2006
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Able to give informed consent for SELENIB. \- An initial diagnosis of: Histopathologically confirmed non\-muscle\-invasive transitional cell carcinoma (Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Disease characteristics – stage pT2 and above • Patients that are pregnant or breastfeeding • Patients diagnosed with HIV infection • Patients who are on immunosuppressive therapy following organ transplantion • Patients taking cyclosporin • Any condition which, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the trial objectives.

Outcomes

Primary Outcomes

Not specified

Similar Trials